HOW THE U.S. STANDS TO BENEFIT FROM BETTER REGULATORY PRACTICES IN CHINA
Including More Timely Import Approvals of Biotech Products

Over the past decade, China has emerged as one of the most valuable export markets for U.S. agricultural products. In 2017 China purchased nearly $20 billion worth of American agricultural products, roughly 63 percent of which were biotech-derived plant products. However, delays in Chinese biotech import approvals have prevented farmers from accessing new technologies and benefitting from productivity gains.

Significant impact in the U.S. from delayed import approvals in China
As summarized below, Informa recently conducted analysis of economic hardships resulting from import approval delays over the past five years, and also projected the significant value to be unlocked with timelier and more predictable biotech import approvals from China.

PLANT BIOTECH INNOVATIONS OFFER MANY BENEFITS TO FARMERS
• Farm income growth ($6.9 billion increase in 2015)
• New and improved ways to manage unpredictable growing seasons (e.g. drought-tolerant crops)
• Fewer natural resources required for cultivation
• More sustainable agricultural practices (e.g. no-till farming)
• Reductions in greenhouse gas emissions
• Better ability to manage pests without resistance evolving

There are mutual benefits for China and the U.S. from more timely biotech import approvals - including increased food security and decreased food prices for Chinese consumers and increased farmer incomes and gains in sustainable farming practices for American farmers.

RISING PRODUCTIVITY PER EACH AMERICAN FARMER

<table>
<thead>
<tr>
<th>Timeframe</th>
<th>1970s</th>
<th>TODAY</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enough to feed</td>
<td>73</td>
<td>155</td>
</tr>
</tbody>
</table>

...in large part to due to plant biotechnology